Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AML-13: G-CSF and Consolidation in Elderly AML
NCT00002719Phase 3Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Dec 1995
- Primary completion
- Nov 2001
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of filgrastim in acute myeloid leukemia (AML) (7 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Overall Survival. Started Dec 1995; status: completed.
02
Drugs
filgrastim
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00002719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002719.